Clinical trials: Malignant Peritoneal Effusion
Ovarian Cancer With Malignant Ascites
Clinical Study in Treatment of Malignant Ascites of Ovarian Cancer With Intraperitoneal Injection Bevacizumab Combined With Intraperitoneal Hyperthermic Perfusion Chemotherapy
To study the efficacy and safety of intraperitoneal injection bevacizumab combined with intraperitoneal hyperthermic perfusion chemotherapy in treatment of malignant ascites of ovarian cancer.
- Trial name
- NCT01838538
- Testing
- Bevacizumab, TC:paclitaxel + carboplatin
- Where
- China
- Volunteers
- 54 people
- Sponsor
- Chinese PLA General Hospital
Cancer
Evaluation of the Efficacy of Diuretics for Symptomatic Malignant Ascites Episodes in Advanced Stage of Cancer (DIASC)
While some authors recommend diuretics as the first treatment to initiate for symptoms caused by malignant ascites (MA), their prescription is variable. No randomized, controlled study has assessed their benefit in this context.
- Trial name
- NCT02501213
- Testing
- Spironolactone (+/- Furosemide)
- Where
- 15 sites in France
- Volunteers
- 14 people
- Sponsor
- Centre Oscar Lambret
Gynecologic Cancer
A Study on the Safety and Preliminary Efficacy of NK042 in the Treatment of Malignant Ascites
The purpose of this study is to assess the safety and efficacy of NK042 for treatment of malignant ascites.
- Trial name
- NCT06415500
- Testing
- NK042
- Where
- China
- Volunteers
- 9 people
- Sponsor
- Anhui Provincial Hospital
Ovarian Neoplasms, Ascites
Study of the Effect of Intravenous AVE0005 (VEGF Trap) in Advanced Ovarian Cancer Patients With Recurrent Symptomatic Malignant Ascites
This study was designed to characterize the effect of aflibercept in participants with advanced chemoresistant ovarian cancer. Primary objective: Compare the effect of aflibercept (ziv-aflibercept, AVE0005, VEGF trap, ZALTRAP®)…
- Trial name
- NCT00327444
- Testing
- aflibercept (ziv-aflibercept, AVE0005, VEGF trap, ZALTRAP®)
- Where
- 9 sites in United States, Austria and 7 more
- Volunteers
- 58 people
- Sponsor
- Sanofi
Malignant Ascites
Study With SCB-313 (Recombinant Human TRAIL-Trimer Fusion Protein) for Treatment of Malignant Ascites
1. The safety and tolerability of single-dose of SCB-313 will be evaluated by intraperitoneal injection; 2. The safety and tolerability of repeated-dose of SCB-313 will be evaluated by intraperitoneal injection once a day for 3…
- Trial name
- NCT04051112
- Testing
- SCB-313
- Where
- China
- Volunteers
- 13 people
- Sponsor
- Sichuan Clover Biopharmaceuticals, Inc.
Malignant Ascites, Colorectal Adenocarcinoma
TLR9 Immunotherapy for Peritoneal Carcinomatosis
The goal of this clinical trial is to determine the safety and efficacy of of ACM-CpG for inoperable peritoneal metastases or malignant ascites.
- Conditions
- Malignant Ascites, Colorectal Adenocarcinoma, Peritoneal (Metastatic) Cancer, Appendiceal Adenocarcinoma
- Trial name
- TIPC (NCT07658196)
- Testing
- ACM-CpG
- Where
- United States
- Volunteers
- 24 people
- Sponsor
- Brown University
Refractory Ovarian Cancer With Recurrent Symptomatic Malignant Ascites
Phase 1/2a Two-Arm Dose-Escalation Study of BAX69 in Subjects With Malignant Ascites of Ovarian Cancer
The purpose of this study is to evaluate the safety and tolerability of BAX69 monotherapy given either as intraperitoneal (IP) infusion (Single-Route Arm); or as IP infusion after intravenous (IV) infusion (IV+IP) (Double-Route…
- Trial name
- NCT02540356
- Testing
- BAX69 Single-Route Arm, BAX69 Double-Route Arm
- Where
- 6 sites in United States
- Volunteers
- 2 people
- Sponsor
- Baxalta now part of Shire
Metastatic Cancer
Mitomycin as a Hyperthermic Peritoneal Perfusion in Treating Patients With Malignant Ascites
RATIONALE: Hyperthermia therapy kills tumor cells by heating them to several degrees above normal body temperature. Peritoneal infusion of heated chemotherapy drugs, such as mitomycin, may kill more tumor cells.
- Trial name
- NCT00265863
- Testing
- mitomycin C
- Where
- United States
- Volunteers
- 1 people
- Sponsor
- Masonic Cancer Center, University of Minnesota
Gastric Cancer, Pancreatic Cancer
GAIA-102 Intraperitoneal Administration in Patients With Advanced Gastrointestinal Cancer of Microsatellite Stable With Malignant Ascites
Phase I Part : Confirm the safety of GAIA-102 as a monotherapy or GAIA-102 and pembrolizumab in combination for advanced gastrointestinal cancer of microsatellite stable with malignant ascites, and determine the recommended…
- Trial name
- NCT05438459
- Testing
- GAIA-102, Pembrolizumab, Trifluridine/tipiracil hydrochloride (FTD/TPI)
- Where
- Japan
- Volunteers
- 176 people
- Sponsor
- Kyushu University
Malignant Ascites
Symptomatic Ascites Drainage With a Patient-controlled Vascular Catheter.
The purpose of this study is to determine whether drainage with the usage of a fine, patient-controlled vascular catheter inserted into abdominal cavity is a feasible, safe and effective method in the management of symptomatic…
- Trial name
- NCT02724683
- Testing
- Ascites drainage with vascular catheter., Interview., Quality of life.
- Where
- 2 sites in Czechia, Poland
- Volunteers
- 170 people
- Sponsor
- Maciej Stukan, MD, PhD
EpCam Positive Tumor (e.g.Ovarian, Gastric, Colon, Breast), Malignant Ascites
Study in EpCAM Positive Patients With Symptomatic Malignant Ascites Using Removab Versus an Untreated Control Group
The study will be performed to obtain further efficacy and safety data in order to obtain a marketing authorization (pivotal study). In addition, health economic data are to be collected.
- Trial name
- NCT00836654
- Testing
- Catumaxomab (Removab), paracentesis
- Volunteers
- 258 people
- Sponsor
- Neovii Biotech
Peritoneum Cancer, Peritoneum Neoplasm
International Registry of Patients Treated With Pressurized IntraPeritoneal Aerosol Chemotherapy (PIPAC)
Multicentric, international, web-based prospective documentation of the indications and results of Pressurized Aerosol Chemotherapy (so-called PIPAC or PITAC) for treating malignant pleural and peritoneal diseases.
- Conditions
- Peritoneum Cancer, Peritoneum Neoplasm, Pleural Cancer, Pleural Effusion
- Trial name
- PIPACRegis (NCT03210298)
- Testing
- PIPAC
- Where
- 16 sites in Argentina, Australia and 11 more
- Volunteers
- 1,000 people
- Sponsor
- Sabine Rhode
Fallopian Tube Cancer, Metastatic Cancer
SCH-58500 in Treating Patients With Primary Ovarian, Fallopian Tube, or Peritoneal Cancer (C95084)
RATIONALE: Giving the p53 gene for ovarian, fallopian tube, or peritoneal cancer may inhibit tumor growth. Giving the gene directly into the peritoneum may kill more cancer cells.
- Conditions
- Fallopian Tube Cancer, Metastatic Cancer, Ovarian Cancer, Primary Peritoneal Cavity Cancer
- Trial name
- NCT00002960
- Testing
- recombinant adenovirus-p53 SCH-58500
- Volunteers
- 59 people
- Sponsor
- Merck Sharp & Dohme LLC
Fallopian Tube Cancer, Metastatic Cancer
ILX-295501 in Treating Patients With Stage III or Stage IV Ovarian Cancer That Has Not Responded to Previous Treatment
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. PURPOSE: Phase II trial to study the effectiveness of ILX-295501 in treating patients who have stage III or…
- Conditions
- Fallopian Tube Cancer, Metastatic Cancer, Ovarian Cancer, Primary Peritoneal Cavity Cancer
- Trial name
- NCT00005645
- Testing
- ILX-295501
- Where
- 8 sites in United States
- Sponsor
- Genzyme, a Sanofi Company
Malignant Ascites
Intraperitoneal Immune Checkpoint Inhibitor for Malignant Ascites
This projectis aim to evaluate the efficacy of immune checkpoint inhibitor (pembrolizumab or nivolumab) on the malignant ascites of patients with advanced gastric, pancreatic and biliary tract cancers.
- Trial name
- NCT05745233
- Testing
- Nivolumab, Pembrolizumab
- Where
- Taiwan
- Volunteers
- 30 people
- Sponsor
- China Medical University Hospital
Digestive System Neoplasms
IP rmhTNF-NC + Tislelizumab + Palliat RT for GIT Tumor Malignant Ascites After Failed Std Tx
This study is a prospective, non-randomized, dual-cohort Phase II clinical trial designed to explore the efficacy and safety of radiotherapy combined with intraperitoneal injection of Recombinant Mutant Human Tumor Necrosis…
- Trial name
- NCT07196540
- Testing
- Radiotherapy for large-volume abdominal lesions + whole peritoneal cavity low-dose radiotherapy + rmhTNF-NC + tislelizumab
- Volunteers
- 78 people
- Sponsor
- Sun Yat-sen University
STOMACH NEOPLASM, Gastric Cancer
Lenvatinib in Combination With Nivolumab Plus Chemotherapy in Metastatic Gastric Cancer Patients With Malignant Ascites
To investigate efficacy and safety of lenvatinib in combination with nivolumab plus chemotherapy in gastric cancer patients with peritoneal metastasis and grade ≥ 2 ascites.
- Conditions
- STOMACH NEOPLASM, Gastric Cancer, Gastric Cancer Adenocarcinoma Metastatic
- Trial name
- NCT07149090
- Testing
- Lenvatinib
- Where
- South Korea
- Volunteers
- 61 people
- Sponsor
- Asan Medical Center
Malignant Ascites
A Clinical Study of Intraperitoneal T3011 Given as a Single Agent in Patients With Malignant Ascites Induced by Advanced Colorectal Cancer
This is a prospective, open, single-arm, investigator-initiated clinical study to evaluate the safety and efficacy of intraperitoneal administration of T3011 at different doses in the treatment of malignant ascites induced by…
- Trial name
- NCT06200376
- Testing
- T3011
- Where
- China
- Volunteers
- 10 people
- Sponsor
- West China Hospital
Malignant Ascites, Gastrointestinal Cancers
Bevacizumab as a Palliative Treatment for Patients With Symptomatic Malignant Ascites Due to Advanced-stage Gastrointestinal Cancers
Malignant ascites represents a severe clinical problem for physicians and patients being confronted with this common symptom of advanced-stage gastrointestinal cancer.
- Trial name
- NCT01200121
- Testing
- Bevacizumab
- Where
- 26 sites in Germany
- Volunteers
- 53 people
- Sponsor
- AIO-Studien-gGmbH
Malignant Ascites
PD-1 Inhibitor Intraperitoneal Perfusion Combined With PRaG Therapy for Malignant Ascites
The effect and safety of intraperitoneal infusion of PD-1 inhibitor is unclear for patients with peritoneal metastasis of advanced malignant tumors and malignant ascites.
- Trial name
- NCT05501340
- Testing
- Serplulimab, Molgramostim, Hypofractionated radiotherapy/Sterotactic body radiotherapy
- Volunteers
- 40 people
- Sponsor
- Second Affiliated Hospital of Soochow University